

REMARKS

In response to the outstanding Restriction Requirement mailed March 20, 2008, Applicants elect Invention 7, claim 100, for examination, with traverse. Applicants respectfully request that Inventions 7, 9 and 11 be combined into a single group because in each, the molecule is an allergen, a viral antigen, or a tumor antigen. No justification was provided to restrict the molecule into three separate groups. Thus, Applicants propose that Invention 7, 9 and 11 be combined into a single Group for restriction purposes, and that if an election of species is necessary, Applicants elect the invention in which the molecule is an allergen.

Claims 81-137 have been cancelled without prejudice and new claims 138-169 have been added. No new matter has been added. New claims 138-169 are directed to the invention of claim 100. Therefore, claims 138-169 read on the elected invention.

Applicants acknowledge the mention of Ko *et al.*, J. Formos. Med. Assoc., 96(7):517-524. New claims 138-169 are patentable over this reference.

Claims 138-169 are currently pending.


CONCLUSION

Applicant believes that the claims are in condition for allowance.

Should any fees be required by the present Reply, the Commissioner is hereby authorized to charge Deposit Account 19-4293.

Respectfully submitted,

Date: 5-20-08
Customer Number: 27890
STEPTOE & JOHNSON LLP
1330 Connecticut Ave., NW
Washington, DC 20036
Tel: 202-429-3000
Fax: 202-429-3902


Harold H. Fox
Reg. No. 41,498